A citation-based method for searching scientific literature

Sourav Banerjee, Tiantian Wei, Jue Wang, Jenna J Lee, Haydee L Gutierrez, Owen Chapman, Sandra E Wiley, Joshua E Mayfield, Vasudha Tandon, Edwin F Juarez, Lukas Chavez, Ruqi Liang, Robert L Sah, Caitlin Costello, Jill P Mesirov, Laureano de la Vega, Kimberly L Cooper, Jack E Dixon, Junyu Xiao, Xiaoguang Lei. Proc Natl Acad Sci U S A 2019
Times Cited: 22







List of co-cited articles
178 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Xing Guo, Xiaorong Wang, Zhiping Wang, Sourav Banerjee, Jing Yang, Lan Huang, Jack E Dixon. Nat Cell Biol 2016
103
54

Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Sourav Banerjee, Chenggong Ji, Joshua E Mayfield, Apollina Goel, Junyu Xiao, Jack E Dixon, Xing Guo. Proc Natl Acad Sci U S A 2018
66
45

DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage.
Naoe Taira, Keishi Nihira, Tomoko Yamaguchi, Yoshio Miki, Kiyotsugu Yoshida. Mol Cell 2007
208
36


DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
Naoe Taira, Rei Mimoto, Morito Kurata, Tomoko Yamaguchi, Masanobu Kitagawa, Yoshio Miki, Kiyotsugu Yoshida. J Clin Invest 2012
93
31

DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Rei Mimoto, Naoe Taira, Hiroyuki Takahashi, Tomoko Yamaguchi, Masataka Okabe, Ken Uchida, Yoshio Miki, Kiyotsugu Yoshida. Cancer Lett 2013
53
27

Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Haiyan Yan, Kaishun Hu, Wenjing Wu, Yu Li, Huan Tian, Zhonghua Chu, H Phillip Koeffler, Dong Yin. PLoS One 2016
20
30


Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
R Mimoto, Y Imawari, S Hirooka, H Takeyama, K Yoshida. Oncogene 2017
20
30

Regulation of Glioma Cells Migration by DYRK2.
Yifen Shen, Li Zhang, Donglin Wang, Yifeng Bao, Chao Liu, Zhiwei Xu, Wei Huang, Chun Cheng. Neurochem Res 2017
10
60

Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways.
Moisés Pérez, Carmen García-Limones, Inés Zapico, Anabel Marina, M Lienhard Schmitz, Eduardo Muñoz, Marco A Calzado. J Mol Cell Biol 2012
43
27

Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition.
Meera Soundararajan, Annette K Roos, Pavel Savitsky, Panagis Filippakopoulos, Arminja N Kettenbach, Jesper V Olsen, Scott A Gerber, Jeyanthy Eswaran, Stefan Knapp, Jonathan M Elkins. Structure 2013
95
27

Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases.
Alejandro Correa-Sáez, Rafael Jiménez-Izquierdo, Martín Garrido-Rodríguez, Rosario Morrugares, Eduardo Muñoz, Marco A Calzado. Cell Mol Life Sci 2020
13
46

The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress.
Rita Moreno, Sourav Banerjee, Angus W Jackson, Jean Quinn, Gregg Baillie, Jack E Dixon, Albena T Dinkova-Kostova, Joanne Edwards, Laureano de la Vega. Cell Death Differ 2021
11
54


DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Noriko Yamaguchi, Rei Mimoto, Nozomu Yanaihara, Yoshimi Imawari, Shinichi Hirooka, Aikou Okamoto, Kiyotsugu Yoshida. Tumour Biol 2015
28
22

Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs.
Pamela A Lochhead, Gary Sibbet, Nick Morrice, Vaughn Cleghon. Cell 2005
211
22

Multiple functions of DYRK2 in cancer and tissue development.
Saishu Yoshida, Kiyotsugu Yoshida. FEBS Lett 2019
20
25

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.
Yasushi Ogawa, Yosuke Nonaka, Toshiyasu Goto, Eriko Ohnishi, Toshiyuki Hiramatsu, Isao Kii, Miyo Yoshida, Teikichi Ikura, Hiroshi Onogi, Hiroshi Shibuya,[...]. Nat Commun 2010
176
22

The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer.
Paula Moreno, Maribel Lara-Chica, Rafael Soler-Torronteras, Teresa Caro, Manuel Medina, Antonio Álvarez, Ángel Salvatierra, Eduardo Muñoz, Marco A Calzado. PLoS One 2015
14
35

A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells.
Chun Shik Park, Andrew H Lewis, Taylor J Chen, Cory S Bridges, Ye Shen, Koramit Suppipat, Monica Puppi, Julie A Tomolonis, Paul D Pang, Toni-Ann Mistretta,[...]. Blood 2019
26
22

Impairment of DYRK2 by DNMT1‑mediated transcription augments carcinogenesis in human colorectal cancer.
Tomotaka Kumamoto, Kohji Yamada, Saishu Yoshida, Katsuhiko Aoki, Shinichi Hirooka, Ken Eto, Katsuhiko Yanaga, Kiyotsugu Yoshida. Int J Oncol 2020
10
50

Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
Shiho Yokoyama-Mashima, Satomi Yogosawa, Yumi Kanegae, Shinichi Hirooka, Saishu Yoshida, Takashi Horiuchi, Toya Ohashi, Katsuhiko Yanaga, Masayuki Saruta, Tsunekazu Oikawa,[...]. Cancer Lett 2019
16
31

Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation.
Hae-Yun Jung, Xin Wang, Sohee Jun, Jae-Il Park. J Biol Chem 2013
45
22

The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities.
Jacopo Boni, Carlota Rubio-Perez, Nuria López-Bigas, Cristina Fillat, Susana de la Luna. Cancers (Basel) 2020
26
22

Emerging roles of DYRK2 in cancer.
Vasudha Tandon, Laureano de la Vega, Sourav Banerjee. J Biol Chem 2021
15
33

Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.
Shin-ichi Yamashita, Masao Chujo, Keita Tokuishi, Kentaro Anami, Michiyo Miyawaki, Satoshi Yamamoto, Katsunobu Kawahara. J Thorac Cardiovasc Surg 2009
12
33

A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT.
Yousang Gwack, Sonia Sharma, Julie Nardone, Bogdan Tanasa, Alina Iuga, Sonal Srikanth, Heidi Okamura, Diana Bolton, Stefan Feske, Patrick G Hogan,[...]. Nature 2006
287
18

Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2.
Rosario Morrugares, Alejandro Correa-Sáez, Rita Moreno, Martín Garrido-Rodríguez, Eduardo Muñoz, Laureano de la Vega, Marco A Calzado. Cell Mol Life Sci 2020
10
40

Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Daisuke Ito, Satomi Yogosawa, Rei Mimoto, Shinichi Hirooka, Takashi Horiuchi, Ken Eto, Katsuhiko Yanaga, Kiyotsugu Yoshida. Cancer Sci 2017
20
20

Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma.
Xiubing Zhang, Pan Xu, Wenkai Ni, Hui Fan, Jian Xu, Yongmei Chen, Wei Huang, Shumin Lu, Li Liang, Jinxia Liu,[...]. Pathol Res Pract 2016
24
18

ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the apoptotic response to DNA damage.
Naoe Taira, Hiroyuki Yamamoto, Tomoko Yamaguchi, Yoshio Miki, Kiyotsugu Yoshida. J Biol Chem 2010
51
18

Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
Nora Göckler, Guillermo Jofre, Chrisovalantis Papadopoulos, Ulf Soppa, Francisco J Tejedor, Walter Becker. FEBS J 2009
166
18


Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.
Charles T Miller, Sanjeev Aggarwal, Theodore K Lin, Susan L Dagenais, Jorge I Contreras, Mark B Orringer, Thomas W Glover, David G Beer, Lin Lin. Cancer Res 2003
46
18

Characterization of a domain that transiently converts class 2 DYRKs into intramolecular tyrosine kinases.
Ross Kinstrie, Nathan Luebbering, Diego Miranda-Saavedra, Gary Sibbet, Jingfen Han, Pamela A Lochhead, Vaughn Cleghon. Sci Signal 2010
30
18

Specificity determinants of substrate recognition by the protein kinase DYRK1A.
S Himpel, W Tegge, R Frank, S Leder, H G Joost, W Becker. J Biol Chem 2000
181
18

A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.
Hyeongki Kim, Kyu-Sun Lee, Ae-Kyeong Kim, Miri Choi, Kwangman Choi, Mingu Kang, Seung-Wook Chi, Min-Sung Lee, Jeong-Soo Lee, So-Young Lee,[...]. Dis Model Mech 2016
57
18

The protein kinase complement of the human genome.
G Manning, D B Whyte, R Martinez, T Hunter, S Sudarsanam. Science 2002
18

Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes.
Martin Mehnert, Rodolfo Ciuffa, Fabian Frommelt, Federico Uliana, Audrey van Drogen, Kilian Ruminski, Matthias Gstaiger, Ruedi Aebersold. Nat Commun 2020
17
23

Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Dnyandev B Jarhad, Karishma K Mashelkar, Hong-Rae Kim, Minsoo Noh, Lak Shin Jeong. J Med Chem 2018
50
18

The selectivity of protein kinase inhibitors: a further update.
Jenny Bain, Lorna Plater, Matt Elliott, Natalia Shpiro, C James Hastie, Hilary McLauchlan, Iva Klevernic, J Simon C Arthur, Dario R Alessi, Philip Cohen. Biochem J 2007
18

Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling.
Frank Wippich, Bernd Bodenmiller, Maria Gustafsson Trajkovska, Stefanie Wanka, Ruedi Aebersold, Lucas Pelkmans. Cell 2013
352
18

Reversible phosphorylation of Rpn1 regulates 26S proteasome assembly and function.
Xiaoyan Liu, Weidi Xiao, Yanan Zhang, Sandra E Wiley, Tao Zuo, Yingying Zheng, Natalie Chen, Lu Chen, Xiaorong Wang, Yawen Zheng,[...]. Proc Natl Acad Sci U S A 2020
21
19

An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases.
Apirat Chaikuad, Julien Diharce, Martin Schröder, Alicia Foucourt, Bertrand Leblond, Anne-Sophie Casagrande, Laurent Désiré, Pascal Bonnet, Stefan Knapp, Thierry Besson. J Med Chem 2016
26
18


Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases.
Vassilios Myrianthopoulos, Marina Kritsanida, Nicolas Gaboriaud-Kolar, Prokopios Magiatis, Yoan Ferandin, Emilie Durieu, Olivier Lozach, Daniel Cappel, Meera Soundararajan, Panagis Filippakopoulos,[...]. ACS Med Chem Lett 2013
49
13

Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
Gregory D Cuny, Natalia P Ulyanova, Debasis Patnaik, Ji-Feng Liu, Xiangjie Lin, Ken Auerbach, Soumya S Ray, Jun Xian, Marcie A Glicksman, Ross L Stein,[...]. Bioorg Med Chem Lett 2012
46
13

Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Yuchan Wang, Yaxun Wu, Xiaobing Miao, Xinghua Zhu, Xianjing Miao, Yunhua He, Fei Zhong, Linlin Ding, Jing Liu, Jie Tang,[...]. Int J Biol Macromol 2015
12
25

Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy.
Shunichiro Nomura, Yasutomo Suzuki, Ryo Takahashi, Mika Terasaki, Ryoji Kimata, Yasuhiro Terasaki, Tsutomu Hamasaki, Go Kimura, Akira Shimizu, Yukihiro Kondo. BMC Urol 2015
17
17


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.